SCHEDULE 13D/A 0001654954-19-014157 0001645469 XXXXXXXX LIVE 1 Common Stock, $0.001 par value 12/09/2024 false 0001727356 61023L207 Gem Pharmaceuticals LLC

200 RANDOLPH AVENUE 200 RANDOLPH AVENUE HUNSTVILLE AL 35801

Gem Pharmaceuticals, LLC 256-539-6000 200 Randolph Avenue Huntsville AL 35801 0001645469 N Monopar Therapeutics OO N DE 611079.00 0.00 611079.00 0.00 611079.00 N 11.6 OO 0001727478 N Hendricks Diane OO N X1 93750.00 611079.00 93750.00 611079.00 704829.00 N 13.4 IN 0001727480 N Leo Karl OO N X1 31312.00 611079.00 31312.00 611079.00 642391.00 N 13.4 IN 0001727496 N Pharma Investments LLC OO N X1 0.00 611079.00 0.00 611079.00 611079.00 N 11.6 OO Common Stock, $0.001 par value Gem Pharmaceuticals LLC 200 RANDOLPH AVENUE 200 RANDOLPH AVENUE HUNSTVILLE AL 35801 Refer to the cover pages. All percentages are calculated based on 5,277,796 shares of Common Stock outstanding as of December 16, 2024. Refer to the cover pages. All percentages are calculated based on 5,277,796 shares of Common Stock outstanding as of December 16, 2024. Except as described in Item 6, the the Reporting Persons have not effected any transaction in the securities of the Issuer during the past 60 days. Not applicable. Not applicable. On December 9, 2024, TacticGem LLC ("TacticGem") made a pro rata distribution of all of the shares of Common Stock that were held by it to its members, Tactic Pharma and Gem Pharmaceuticals, LLC ("Gem"). In such distribution, Gem received the 611,079 shares of Common Stock that were already attributed to Gem (after giving effect to a prior 1 to 5 reverse split that reduced the 3,055,394 shares referenced in the original filing to such 611,079 shares). Gem and the other Reporting Persons were already deemed to beneficially own their pro rata interest in the shares held indirectly by Gem, so the distribution did not result in any change to the beneficial ownership of the Reporting Persons. The Reporting Persons and Gem agreed to lock-up provisions with each other prohibiting sales of the distributed Common Stock until December 31, 2025, without the mutual consent of representatives of Gem. In addition, the Reporting Persons will continue to have the same registration rights previously exercisable through Gem, but the lock-up agreement also provided that neither the Reporting Persons nor Gem would exercise such rights until December 31, 2025, without the mutual consent of representatives of Gem. Monopar Therapeutics Karl Leo 12/18/2024 Hendricks Diane Diane Hendricks 12/18/2024 Leo Karl Karl Leo 12/18/2024 Pharma Investments LLC Diane Hendricks 12/18/2024